NASDAQ:MPLT

Maplight Therapeutics Q3 2026 Earnings Results & Report

Maplight Therapeutics logo
$6.54 -0.36 (-5.22%)
As of 11:26 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Maplight Therapeutics beat analyst earnings expectations in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$0.97 versus the -$1.22 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call Date
Conference Call
4:00 PM ET

Maplight Therapeutics EPS Results

Actual EPS
-$0.97
Consensus EPS
-$1.22
Beat/Miss
Beat by +$0.25
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 5 quarters

Maplight Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Maplight Therapeutics Q3 2026 Earnings FAQ

Maplight Therapeutics (NASDAQ:MPLT) reported earnings of -$0.97 per share for Q3 2026, beating the consensus estimate of -$1.22. The report was announced on Monday, November 16, 2026.

Maplight Therapeutics Earnings Headlines

Top Trader Reveals Stunning Black Friday Deal
Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
See More Maplight Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Maplight Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Maplight Therapeutics and other key companies, straight to your email.

About Maplight Therapeutics

Maplight Therapeutics (NASDAQ:MPLT) is a clinical-stage biopharmaceutical company developing medicines for people with serious brain disorders. Its research focuses on treatments intended to address symptoms that can be difficult to manage with existing therapies.

The company’s investigational programs include ML-007 for schizophrenia and ML-004 for autism spectrum disorder. These candidates remain in development and are not approved medicines.

View Maplight Therapeutics Profile